Lilly funds a UK trial testing whether weight-loss drugs affect employment

Eli Lilly has committed £279 million ($364 million) to the United Kingdom, including funding for a five-year study that will track whether tirzepatide affects employment status and sick days among people treated for obesity ^[1][2]. The deal, announced October 15, 2024, came alongside a wider £63 billion package of investments tied to the UK Labour government's first International Investment Summit ^[1].

The study, called SURMOUNT-REAL UK, will be run with Health Innovation Manchester and will look at tirzepatide's real-world effects on weight loss, diabetes prevention, and prevention of obesity-related complications ^[2]. Tirzepatide is the active ingredient in Lilly's Zepbound and Mounjaro ^[1][2]. Alongside those clinical measures, researchers will also track participants' job status and how many sick days they take from work ^[1][2].

UK health officials framed the trial in economic terms. Health and Social Care Secretary Wes Streeting said obesity-related illness leads to about four extra sick days a year on average and costs the National Health Service roughly £11 billion annually ^[1][2]. He argued that weight-loss drugs could be "monumental" for getting people back to work, while also cautioning that "the NHS can't be expected to always pick up the tab for unhealthy lifestyles" ^[1]. In England, about 64% of adults are overweight or living with obesity, according to the 2022 Health Survey for England ^[2].

Not everyone welcomed the framing. Dr. Dolly van Tulleken, a visiting researcher at the University of Cambridge's MRC epidemiology unit, told BBC Radio 4 that tying health treatment to employment outcomes raises "serious ethical, financial and efficacy considerations," including the risk of measuring people's value by economic output rather than health need ^[1]. Citi analyst Peter Verdault noted separately that the broader body of evidence supporting wider use of weight-loss drugs "keeps coming" ^[1].

The £279 million package also funds Lilly's first European "Lilly Gateway Labs" site, an accelerator for early-stage life sciences companies, with up to £204 million allocated over three years for that effort ^[2]. Lilly said it expects to invest an additional £279 million in the UK in coming years ^[1].

Why it matters for patients

This trial is happening in the UK's National Health Service, not the US system, so no American patient will be enrolled in it. But the study matters to US readers because it is designed to produce a new kind of evidence: proof that obesity drugs pay for themselves not just through better health, but through fewer missed workdays and more people employed ^[1][2]. That is exactly the kind of argument that could be used with US employers and insurers, who often decide whether to cover GLP-1 drugs based on cost, not just clinical benefit.

If the Manchester study finds a link between treatment and employment, expect that data to show up in pitches to US payers weighing coverage decisions. If it does not, or if the effect is small, that could also shape those conversations. Either way, the skepticism raised by researchers like van Tulleken is a reminder that linking medical treatment to work status is contested, not settled science ^[1].

What happens next

The study is described as a five-year real-world evidence effort, meaning results are not expected quickly ^[1][2]. Lilly said the collaboration is subject to relevant approvals before it can begin in full ^[2]. In the meantime, the UK's National Institute for Health and Care Excellence has already recommended a phased rollout of tirzepatide to nearly a quarter of a million NHS patients over three years, starting with those who have multiple obesity-related complications ^[2], a rollout that will generate its own data well before the employment study concludes.